



## YOSRA BOURAOUI

Phone: (216) 20561679  
Yosra\_132001@yahoo.fr

Immeuble Bel Hadj N°1  
Rue Konstantine Bizerte 7000,  
Tunisia

### EDUCATION

**PhD University of Carthage**, Faculty of Sciences Bizerte, Unit IMEC, Date 01<sup>st</sup> April, 2010: Diploma: Doctorate

**MS University of Carthage**, Faculty of Sciences Bizerte, Unit IMEC, Date 27<sup>th</sup> December, 2003

**BS University of Monastir** , Faculty of Sciences of Monastir, Biological Sciences, Date, June 2001

### Professional Position

**Titular Assistant Professor of Immunology** *University of Jendouba*, Biotechnology Institute of Beja, Tunisia 2012 until now

**Assistant Professor under Contract** ; University of Monastir For 2 years: 2010-2011

**Scientist Research** at Unit Immuni-Microbio Environmental and Carcinogenesis (IMEC) Faculty of Sciences of Bizerte, Tunisia

**Topic:** Tumor Immunology and cellular Signaling pathways in prostatic pathologies

**RESEARCH  
TRAINING**

**Grant Award from DAAD: Research stays for University  
Academic and Scientist**

Molecular Bioinformatic group: Institute of Informatics, Goethe  
University , **Frankfurt, Germany**, Date 26/06/2017 to 25/07/2017

-Molecular Bioinformatic group: Institute of Informatics, Goethe  
University , **Frankfurt, Germany**, 1/06/2014 to 15/06/2014  
07/12/2014to 23/12/2014

-**Spanish-Tunisian Project**, Department of Genetics and cell  
biology, Alacala University, **Madrid**, Spain, Date October-  
November 2008

Subject: signaling pathways TRAF6/TRAF2 and NFkB  
in human prostatic pathologies according PSA levels

**PhD Fellowship** from Tunisia, Department of Urology, Faculty  
of Medecine, University of **Innsbruck, Austria**, Date: October-  
November 2006

**PhD Fellowship** from Tunisia Department of Genetics and cell  
biology, Alacala University, **Madrid**, Spain, Date October-  
November-December 2005

-

**MEMBERSHIP**

**Association: European Association of Cancer Research  
(EACR)**

**LANGUAGES**

**Arabic and French: Native Language**

**English: Advanced listening, Reading and Writing**

**Germany: Poor**

**Methods Skills**

**Immunohistochemistry, Western Blot, Cell culture, PCR, ELISA  
Bioinformatic: Petri nets**

## List of Academic Publications

### 2016-2015

1-JEMAA AB, BOURAOU Y, ET AL. CYTOKINE PROFILING IDENTIFIES AN INTERACTION OF IL-6 AND IL-1A TO DRIVE PSMA-PSA PROSTATE CLONES. IMMUNOBIOLOGY. 2016 JUL 15

2-JEMAA AB, BOURAOU Y, ET AL. PSMA-PSA CLONES CONTROLLED BY FULL AKT PHOSPHORYLATION (T308+,S473+) RECAPITULATE MOLECULAR FEATURES OF HUMAN PROSTATE CANCER. TUNIS MED. 2015 AUG-SEP;93(8-9):556-64.

### 2014-2013

1-JEMAA AB, BOURAOU Y, ET AL. INSIGHT INTO THE HETEROGENEITY OF PROSTATE CANCER THROUGH PSA-PSMA PROSTATE CLONES: MECHANISMS AND CONSEQUENCES. HISTOL HISTOPATHOL. 2014 OCT;29(10):1263-80

2-Jemaa AB, Bouraoui Y, et al. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer. *J Immunoassay Immunochem*. 2014;35(1):48-59. doi: 10.1080/15321819.2013.792830.

3- BEN JEMAA A, BOURAOU Y, ET AL. PSA-PSMA PROFILES AND THEIR IMPACT ON SERA PSA LEVELS AND ANGIOGENIC ACTIVITY IN HYPERPLASIA AND HUMAN PROSTATE CANCER. PATHOL BIOL (PARIS). 2014 JUN;62(3):129-36. DOI: 10.1016/J.PATBIO.2014.02.012

4-Ben Jemaa A, Bouraoui Y, et al. A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP. *Biomed Res Int*. 2013; 2013:409179. doi: 10.1155/2013/409179.

5-Ben Jemaa A, Bouraoui Y, et al. Involvement of AKT activation (T308/S473) on PSMA-PSA profiles in benign prostatic hyperplasia and prostate cancer. *Journal of Biological Research-Thessaloniki* 20: 175–184, 2013

6- Ben Jemaa A, Bouraoui Y, et al. Cellular distribution and heterogeneity of PSA and PSMA expression in normal, hyperplasia and human prostate cancer. *Tunis Med*. 2013 Jul;91(7):458-63.

## 2012-2010

**1-Bouraoui Y** , Ben Jemaa A, et al. TRAF-2/ASK-1/P38/NF-kB pathways in normal prostate, benign prostate hyperplasia and prostate cancer. *Journal of Biological Research-Thessaloniki* **18: 301– 309, 2012**

**2- Bouraoui Y** et al. Down regulation of Prostate Specific Antigen by IL-1 beta Mediated NF-Kappa B Contributes to Inhibition of Cell Proliferation in LNCaP prostate cancer cell line. *Cell Biol International* **36,449-454 2012**

**3-Bouraoui Y** et al. Profile of NF-KB (p50/p65) among Prostate Specific Antigen sera levels in prostatic pathologies. *Pathol Biol (Paris)* .**2012 Oct; 60 (5) :301-5. doi10.1016/j.**

**4-Cansino JR, Vera R, Rodríguez de Bethencourt F, Bouraoui Y, Rodríguez G, Prieto A, de la Peña J, Paniagua R, Royuela M.** Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy. *Actas Urol Esp.* **2011 Jan;35(1):16-21. doi: 10.1016/j.acuro**

**5-Ben Jemaa A, Bouraoui Y,** et al. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. *Journal Experimental and Clinical Cancer Research* **2010,29 : 117**

**6-Rodríguez-Berriguete G, Prieto A, Fraile B, Bouraoui Y, de Bethencourt FR, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M.** Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland. *Eur Cytokine Netw.* **2010 Dec;21(4):241-50. doi: 10.1684/ecn.2010.0211**

## 2009-2006

**1Bouraoui Mechergui Yosra** et al. The Profile of Prostate Epithelial Cytokines and its Impact on Sera Prostate Specific Antigen Levels. *Inflammation, Vol. 32, No. 3, 2009 p 202-210 .*

**2- Bouraoui Y et al.** Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. *Cancer Detection and Prevention* **32 (2008) p 23-32**

**3- Bouraoui Y et al.** Relation between sera prostate specific antigen levels and interleukin-6 in prostate tissue of patients with benign hyperplasia and prostate cancer: A Tunisian study. *Revue Internationale des Services de Santé Des Forces Armées. Vol 81p31-36, 2008. ISSN: 0259-8582.*

**4-Bouraoui.Y et al.** Evolutions des formes moléculaires de l'Antigène Spécifique de la prostate chez des groupes sérologiques de patients atteints de pathologies prostatiques. *Immuno-Analyse et Biologie Spécialisée (IBS)* **21 (2006) p286-291. \_ISSN: 0923-2532**